Lincoln National Corporation’s Board of Directors Declares Quarterly Cash Dividend

Lincoln National Corporation’s Board of Directors Declares Quarterly Cash Dividend

RADNOR, Pa.–(BUSINESS WIRE)–
Lincoln Financial (NYSE:LNC) announced today that the board of directors of Lincoln National Corporation declared a quarterly cash dividend of $0.45 per share on the corporation’s common stock. The dividend on the common stock will be payable May 1, 2025 to shareholders of record at the close of business on April 10, 2025.

About Lincoln Financial

Lincoln Financial helps people confidently plan for their vision of a successful financial future. As of December 31, 2024, approximately 17 million customers trust our guidance and solutions across four core businesses – annuities, life insurance, group protection, and retirement plan services. As of December 31, 2024, the company had $321 billion in end-of-period account balances, net of reinsurance. Headquartered in Radnor, PA., Lincoln Financial is the marketing name for Lincoln National Corporation (NYSE: LNC) and its affiliates. Learn more at LincolnFinancial.com.

Tina Madon

Investor Relations

[email protected]

Sarah Boxler

Media Relations

[email protected]

KEYWORDS: United States North America Pennsylvania

INDUSTRY KEYWORDS: Personal Finance Finance Professional Services Asset Management Insurance

MEDIA:

Logo
Logo

NewGen Issues Clarification on Press Release Titled “NewGen Receives Continued Nasdaq Listing Approval and Announces New Business Development Director” dated February 20, 2025

BANGKOK, Feb. 21, 2025 (GLOBE NEWSWIRE) — NewGenIvf Group Limited (NASDAQ: NIVF) (“NewGen” or the “Company”) today issued a clarification that, in the press release titled “NewGen Receives Continued Nasdaq Listing Approval and Announces New Business Development Director” issued on February 20, 2025, the Company did not intend to imply that it has already achieved compliance with the Nasdaq Capital Market’s $2.5 million minimum stockholders’ equity requirement (the “Equity Rule”). However, during its 1st quarter to date, certain NewGen debtholders converted $2.3 million of debt to equity and the Company has drawn down approximately $4.3 million from its Equity Line of Credit with White Lion Capital. Therefore, the Company believes it has in excess of $2.5 million in stockholders’ equity as of this date. The Company is awaiting confirmation from Nasdaq that it has evidenced compliance with the Equity Rule. However, there can be no assurance that Nasdaq will determine that the Company has regained compliance with the Nasdaq continued listing rules.

NewGen further confirms that the Nasdaq Hearings Panel (the “Panel”) granted an extension, allowing the Company additional time to regain compliance with Nasdaq’s continued listing requirements, subject to meeting specific compliance criteria within designated timeframes. In accordance with the Panel’s extension, the Company has already made progress on its compliance plan (along with the update on the Equity Rule already noted above), including carrying out a reverse split on February 11, 2025 in order to regain compliance with the $1.00 bid price requirement (NewGen’s closing bid price has traded above $1.00 for six consecutive trading days as of February 19, 2025). The Company also intends to apply for transition to the Nasdaq Capital Market on or before February 26, 2025.  

About NewGen

NewGen is a comprehensive fertility services provider in Asia helping couples and individuals obtain access to fertility treatments. With a mission to aid couples and individuals in building families regardless of fertility challenges, NewGen has dedicated itself to creating increased access to infertility treatment and providing comprehensive fertility services for its customers. NewGen’s management team collectively has over a decade of experience in the fertility industry. NewGen’s clinics are located in Thailand, Cambodia, and Kyrgyzstan, and present a full suite of services for its patients, including comprehensive infertility and assisted reproductive technology treatments, egg and sperm donation, and surrogacy, in the appropriate jurisdictions, respectively. To learn more, visit www.newgenivf.com. The information contained on, or accessible through, NewGen’s website is not incorporated by reference into this press release, and you should not consider it a part of this press release.

Forward-Looking Statements

This press release contains forward-looking statements. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements generally are identified by the words “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions. Without limiting the generality of the foregoing, the forward-looking statements in this press release include descriptions of the Company’s future commercial operations, business strategy, and financial condition. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release. You should carefully consider the foregoing factors and the other risks and uncertainties described in the Company’s annual report on Form 20-F and other documents filed or to be filed by the Company with the SEC from time to time, which could cause actual events and results to differ materially from those contained in the forward-looking statements. Copies of these documents are available on the SEC’s website, www.sec.gov. All information provided herein is as of the date of this press release, and the Company undertakes no obligation to update any forward-looking statement, except as required under applicable law.

Investor Relations Contact

ICR, LLC
Robin Yang
Phone: +1 (212) 537-4406
Email: [email protected]



State Street Corporation Declares Dividends on its Common Stock and Non-Cumulative Perpetual Preferred Stock Series “G,” “I,” and “J”

State Street Corporation Declares Dividends on its Common Stock and Non-Cumulative Perpetual Preferred Stock Series “G,” “I,” and “J”

BOSTON–(BUSINESS WIRE)–
State Street Corporation (NYSE:STT) today announced a quarterly cash dividend of $0.76 per share of common stock, payable on April 11, 2025 to common shareholders of record at the close of business on April 1, 2025.

Additionally, State Street Corporation announced a cash dividend on each of the below outstanding series of non-cumulative perpetual preferred stock:

  • Series G (represented by depositary shares, each representing a 1/4000th interest in a share of Series G preferred stock). The cash dividend is in the amount of $1,337.50 per share of Series G preferred stock (resulting in a distribution of approximately $0.334375 per depositary share) and is payable on March 18, 2025 to the holders of record of the Series G preferred stock at the close of business on March 3, 2025.
  • Series I (represented by depositary shares, each representing a 1/100th interest in a share of Series I preferred stock). The cash dividend is in the amount of $1,675.00 per share of Series I preferred stock (resulting in a distribution of approximately $16.750000 per depositary share) and is payable on March 18, 2025 to the holders of record of the Series I preferred stock at the close of business on March 3, 2025.
  • Series J (represented by depositary shares, each representing a 1/100th interest in a share of Series J preferred stock). The cash dividend is in the amount of $1,675.00 per share of Series J preferred stock (resulting in a distribution of approximately $16.750000 per depositary share) and is payable on March 18, 2025 to the holders of record of the Series J preferred stock at the close of business on March 3, 2025.

About State Street Corporation

State Street Corporation (NYSE: STT) is one of the world’s leading providers of financial services to institutional investors including investment servicing, investment management and investment research and trading. With $46.6 trillion in assets under custody and/or administration and $4.7 trillion* in assets under management as of December 31, 2024, State Street operates globally in more than 100 geographic markets and employs approximately 53,000 worldwide. For more information, visit State Street’s website at www.statestreet.com.

*Assets under management as of December 31, 2024 includes approximately $82 billion of assets with respect to SPDR® products for which State Street Global Advisors Funds Distributors, LLC (SSGA FD) acts solely as the marketing agent. SSGA FD and State Street Global Advisors are affiliated.

Media Contact:

Carolyn Cichon

+1 617 664 8672

Investor Contact:

Elizabeth Lynn

+1 617 664 3477

KEYWORDS: United States North America Massachusetts

INDUSTRY KEYWORDS: Asset Management Professional Services Finance

MEDIA:

Logo
Logo

Serve Robotics to Report 2024 Fourth Quarter and Full Year Financial Results, Host Conference Call and Webcast on March 6

SAN FRANCISCO, Feb. 20, 2025 (GLOBE NEWSWIRE) — Serve Robotics Inc. (Nasdaq: SERV), a leading autonomous sidewalk delivery company, today announced that it will report its 2024 fourth quarter and full year financial results on Thursday, March 6, 2025 after market close. The company will host a conference call and webcast to review the results on the same day.

Conference Call and Webcast Information

Company management will host a conference call at 2:00 p.m. PT / 5:00 p.m. ET. A live audio webcast will be available at investors.serverobotics.com and a replay will be available at the same location.

Analysts and investors who wish to submit questions to management may send an email to [email protected] by close of business on Tuesday, March 4, 2025.

If you wish to receive company email notifications, please register at https://investors.serverobotics.com/ir-resources/email-alerts

About Serve Robotics

Serve Robotics develops advanced, AI-powered, low-emissions sidewalk delivery robots that endeavor to make delivery sustainable and economical. Spun off from Uber in 2021 as an independent company, Serve has completed tens of thousands of deliveries for enterprise partners such as Uber Eats and 7-Eleven. Serve has scalable multi-year contracts, including a signed agreement to deploy up to 2,000 delivery robots on the Uber Eats platform across multiple U.S. markets.

For further information about Serve Robotics (Nasdaq:SERV), please visit www.serverobotics.com or follow us on social media via X (Twitter), Instagram, or LinkedIn @serverobotics.

Contacts

Media

Aduke Thelwell
Head of Communications & Investor Relations
[email protected]

Investor Relations

[email protected]



Elastic to Present in Upcoming Investor Conference

Elastic to Present in Upcoming Investor Conference

SAN FRANCISCO–(BUSINESS WIRE)–
Elastic (NYSE: ESTC), the Search AI Company, announced that its management will present at the Morgan Stanley Technology, Media & Telecom Conference on Wednesday, March 5, 2025 at 1:05 p.m. PT / 4:05 p.m. ET.

A live webcast and replay of the event will be available on Elastic’s Investor Relations page at ir.elastic.co.

About Elastic

Elastic (NYSE: ESTC), the Search AI Company, enables everyone to find the answers they need in real-time using all their data, at scale. Elastic’s solutions for search, observability and security are built on the Elastic Search AI Platform, the development platform used by thousands of companies, including more than 50% of the Fortune 500. Learn more at elastic.co.

Elastic and associated marks are trademarks or registered trademarks of Elastic N.V. and its subsidiaries. All other company and product names may be trademarks of their respective owners.

Anthony Luscri

Elastic Investor Relations

[email protected]

Elastic Corporate Communications

[email protected]

KEYWORDS: United States North America California

INDUSTRY KEYWORDS: Technology Artificial Intelligence Data Management

MEDIA:

Logo
Logo

Drugs Made In America Acquisition Corp. Announces the Separate Trading of its Ordinary Shares and Rights, Commencing February 25, 2025

Fort Lauderdale, Florida, Feb. 20, 2025 (GLOBE NEWSWIRE) — Drugs Made In America Acquisition Corp. (Nasdaq: DMAAU) (the “Company”) today announced that, commencing February 25, 2025, holders of the units sold in the Company’s initial public offering may elect to separately trade the Company’s ordinary shares and rights included in the units.

No fractional rights will be issued upon separation of the units and only whole rights will trade. The ordinary shares and rights that are separated will trade on The Nasdaq Global Market under the symbols “DMAA” and “DMAAR,” respectively. Those units not separated will continue to trade on The Nasdaq Global Market under the symbol “DMAAU.” Holders of units will need to have their brokers contact VStock Transfer LLC, the Company’s transfer agent, in order to separate the units into ordinary shares and rights.

The offering of the units was made only by means of a prospectus, copies of which may be obtained from Clear Street, Attn: Syndicate Department, 150 Greenwich Street, 45th floor, New York, NY 10007, or by email at [email protected]. A registration statement on Form S-1 (333-281170) relating to these securities has been filed with the Securities and Exchange Commission (“SEC”) and was declared effective on January 7, 2025, and a post-effective amendment to the registration statement was declared effective on January 27, 2025. Copies of the registration statement can be accessed through the SEC’s website at www.sec.gov.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Drugs Made In America Acquisition Corp.

The Company is a blank check company incorporated in the Cayman Islands as an exempted company incorporated for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or other similar business combination with one or more businesses. While the Company may pursue a business combination target in any business, industry or geographical location, it intends to focus its search for businesses in the pharmaceutical industry. The Company believes that it is possible to mitigate risks in the U.S. medical supply chain by investing in companies that will reduce America’s overreliance on production of pharmaceuticals from concentrated geographic regions through investments in strategic on-shoring of advanced domestic manufacturing technologies for critical drugs.

Cautionary Note Concerning Forward-Looking Statements

This press release includes forward-looking statements that involve risks and uncertainties. Forward looking statements are statements that are not historical facts. Such forward-looking statements are subject to risks and uncertainties, which could cause actual results to differ from the forward-looking statements. The Company expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in the Company’s expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based. Forward-looking statements are subject to numerous conditions, many of which are beyond the control of the Company, including those set forth in the Risk Factors section of the registration statement, as amended by the post-effective amendment, and the prospectus filed in connection with the initial public offering with the SEC. Copies are available on the SEC’s website, www.sec.gov.

Contact Information

Drugs Made In America Acquisition Corp.
1 East Broward Boulevard, Suite 700
Fort Lauderdale, FL 33301

Lynn Stockwell
Chief Executive Officer and Executive Chair
Email: [email protected]
Phone: (954) 870-3099



IFF Announces Executive Leadership Team Aligned With New Operating Model

IFF Announces Executive Leadership Team Aligned With New Operating Model

NEW YORK–(BUSINESS WIRE)–
IFF (NYSE: IFF) announced changes to its executive leadership team, aligned with the Company’s external reporting structure.

After 21 years of dedicated service to IFF, Simon Herriott, president of Health and Biosciences, will step down. Effective March 1, Leticia Gonçalves, ADM’s president of precision fermentation and ADM Ventures, will join IFF as president of Health and Biosciences.

“Since 2019, Simon has driven growth and operational effectiveness through innovation, customer intimacy and supply chain development as president of our Health and Biosciences business unit,” said Erik Fyrwald, IFF CEO. “We’re grateful for Simon’s tremendous contributions to IFF and wish him well for the future. His dedication and leadership will leave a lasting impact on our organization.”

Gonçalves brings to IFF extensive experience with IFF’s end markets in innovation-based companies, having served in various senior global and regional P&L leadership roles at ADM, Bayer and Monsanto in Brazil, Europe and the United States. She was most recently president of precision fermentation and ventures at ADM, where she developed new businesses to serve growing customer needs across various food, health and wellness, agriculture and industrial applications. She also led ADM’s Specialty Ingredients and Foods businesses driving innovation, culture and productivity to maximize value creation across food security, supply chain resilience and sustainability. She is a board member of Emerson Electric.

“We’re excited to welcome Leticia to IFF,” said Fyrwald. “Her extensive experience driving P&L growth in innovation-led businesses and accelerating high-performing teams—coupled with her knowledge of our end markets—will be a great addition to our leadership team. I’m confident Leticia will continue to build on our cutting-edge biotechnology platform of probiotics, cultures and enzymes and drive our next phase of business growth.”

Also new to the executive leadership team, Andy Muller serves as IFF’s president of Food Ingredients. He joined IFF in December 2024 with a wealth of experience in food ingredients. Most recently, he served as president of Functional Ingredients and Solutions at Corbion where he focused on bakery, meat, dairy, confectionery, beverage industries, pet food and biochemicals. He spent 12 years with Danisco, later DuPont’s Nutrition and Health business, where he grew the business by expanding organizational capabilities, rationalizing the product portfolio, and refocusing efforts on core end-market applications. He serves on the board of PureField Ingredients.

“Andy’s deep experience in food ingredients and knowledge of our business will support our focus to deliver growth in our specialty ingredients business and increased value to our customers. We’re excited to have him on board as we continue to grow and innovate.”

Yuvraj Arora, previously President, Nourish, has assumed the role of President, Taste and Chief Commercial Officer. Ana Paula Mendonça, President, Scent, and Angela Strzelecki, President, Pharma Solutions, maintain their current divisional leadership roles.

IFF’s executive leadership team now includes:

  • Erik Fyrwald, CEO
  • Michael DeVeau, EVP, Chief Financial Officer
  • Yuvraj Arora, President, Taste and Chief Commercial Officer
  • Ana Paula Mendonça, President, Scent
  • Leticia Gonçalves, President, Health & Biosciences
  • Andy Muller, President, Food Ingredients
  • Angela Strzelecki, President, Pharma Solutions
  • Deborah Borg, EVP, Chief People & Culture Officer
  • Ralph Finzel, EVP, Global Operations Officer
  • Vic Verma, EVP, Chief Information Officer
  • Jennifer Johnson, EVP, General Counsel and Corporate Secretary
  • Steve Landsman, EVP, Business Development

Welcome to IFF

At IFF (NYSE: IFF), we make joy through science, creativity and heart. As the global leader in flavors, fragrances, food ingredients, health and biosciences, we deliver groundbreaking, sustainable innovations that elevate everyday products—advancing wellness, delighting the senses and enhancing the human experience.Learn more at iff.com, LinkedIn, Instagram and Facebook.

© 2025 by International Flavors & Fragrances Inc. IFF is a Registered Trademark. All Rights Reserved.

Media Relations:

Paulina Heinkel

332.877.5339

[email protected]

Investor Relations:

Michael Bender

212.708.7263

[email protected]

KEYWORDS: Europe United States North America New York

INDUSTRY KEYWORDS: Professional Services Retail Chemicals/Plastics Manufacturing Finance Other Manufacturing Food/Beverage

MEDIA:

Logo
Logo

BioAge Labs to Participate in TD Cowen’s 45th Annual Health Care Conference

RICHMOND, Calif., Feb. 20, 2025 (GLOBE NEWSWIRE) — BioAge Labs (Nasdaq: BIOA) (“BioAge”, “the Company”), a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging, today announced that the Company will participate in one-on-one meetings at TD Cowen’s 45th Annual Health Care Conference.

TD Cowen’s 45th Annual Health Care Conference is taking place on March 3–5, 2025, at the Boston Marriott Copley Place in Boston, MA. The conference incorporates presentations, fireside chats and innovative panel discussions, moderated by members of the TD Cowen research team, that focus on various aspects of the health care industry.

About BioAge Labs, Inc.

BioAge is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging. The company’s pipeline includes novel, orally available, brain-penetrant small-molecule NLRP3 inhibitors to treat metabolic diseases and conditions driven by neuroinflammation, as well as novel, structurally differentiated APJ agonists for metabolic disorders. BioAge’s additional preclinical programs, which leverage insights from the Company’s proprietary discovery platform built on human longevity data, address key pathways involved in metabolic aging.

Contacts

PR: Chris Patil, [email protected]
IR: Dov Goldstein, [email protected]
Partnering: [email protected]
Web: https://bioagelabs.com



Oaktree Specialty Lending Corporation Prices Public Offering of $300,000,000 6.340% Notes due 2030

LOS ANGELES, CA, Feb. 20, 2025 (GLOBE NEWSWIRE) — Oaktree Specialty Lending Corporation (NASDAQ: OCSL) (“OCSL” or the “Company”), a specialty finance company, today announced that it has priced an underwritten public offering of $300.0 million aggregate principal amount of 6.340% notes due 2030. The notes will mature on February 27, 2030 and may be redeemed in whole or in part at the Company’s option at any time at par plus a “make-whole” premium, if applicable.

OCSL expects to use the net proceeds of this offering to reduce its outstanding debt under its revolving credit facilities and for general corporate purposes.

SMBC Nikko Securities America, Inc., BNP Paribas Securities Corp., ING Financial Markets LLC, Wells Fargo Securities, LLC, BofA Securities, Inc., J.P. Morgan Securities LLC, RBC Capital Markets, LLC, CIBC World Markets Corp., Citigroup Global Markets Inc., Barclays Capital Inc., Deutsche Bank Securities Inc., Goldman Sachs & Co. LLC and Morgan Stanley & Co. LLC are acting as joint book-running managers for this offering. KeyBanc Capital Markets Inc., First Citizens Capital Securities, LLC, Keefe, Bruyette & Woods, Inc., A Stifel Company, R. Seelaus & Co., LLC, B. Riley Securities, Inc., Blaylock Van, LLC, Citizens JMP Securities, LLC, Jefferies LLC and Oppenheimer & Co. Inc. are acting as co-managers for this offering. The offering is expected to close on February 27, 2025, subject to customary closing conditions.

Investors are advised to carefully consider the investment objective, risks, charges and expenses of OCSL before investing. The pricing term sheet dated February 20, 2025, the preliminary prospectus supplement dated February 20, 2025 and the accompanying prospectus dated February 7, 2023, each of which have been filed with the Securities and Exchange Commission, contain this and other information about the Company and should be read carefully before investing.

The pricing term sheet, the preliminary prospectus supplement, the accompanying prospectus and this press release are not offers to sell any securities of OCSL and are not soliciting an offer to buy such securities in any jurisdiction where such offer and sale is not permitted.

The offering may be made only by means of a preliminary prospectus supplement and an accompanying prospectus. Copies of the preliminary prospectus supplement (and accompanying prospectus) may be obtained by calling
SMBC Nikko Securities America, Inc. at 1-212-224-5135, BNP Paribas Securities Corp. at 1-800-854-5674, ING Financial Markets LLC at 1-877-446-4930 or Wells Fargo Securities, LLC at 1-800-645-3751
.

About Oaktree Specialty Lending Corporation

Oaktree Specialty Lending Corporation (NASDAQ:OCSL) is a specialty finance company dedicated to providing customized one-stop credit solutions to companies with limited access to public or syndicated capital markets. The Company’s investment objective is to generate current income and capital appreciation by providing companies with flexible and innovative financing solutions including first and second lien loans, unsecured and mezzanine loans, and preferred equity. The Company is regulated as a business development company under the Investment Company Act of 1940, as amended, and is externally managed by Oaktree Fund Advisors, LLC, an affiliate of Oaktree Capital Management, L.P.

Forward-Looking Statements

Some of the statements in this press release constitute forward-looking statements because they relate to future events, future performance or financial condition. The forward-looking statements may include statements as to: future operating results of the Company and distribution projections; business prospects of the Company and the prospects of its portfolio companies; and the impact of the investments that the Company expects to make. In addition, words such as “anticipate,” “believe,” “expect,” “seek,” “plan,” “should,” “estimate,” “project” and “intend” indicate forward-looking statements, although not all forward-looking statements include these words. The forward-looking statements contained in this press release involve risks and uncertainties. Certain factors could cause actual results and conditions to differ materially from those projected, including the uncertainties associated with (i) changes in the economy, financial markets and political environment, including the impacts of inflation and elevated interest rates; (ii) risks associated with possible disruption in the operations of the Company or the economy generally due to terrorism, war or other geopolitical conflict (including the current conflicts in Ukraine and Israel), natural disasters, pandemics or cybersecurity incidents; (iii) future changes in laws or regulations (including the interpretation of these laws and regulations by regulatory authorities); (iv) conditions in the Company’s operating areas, particularly with respect to business development companies or regulated investment companies; and (v) other considerations that may be disclosed from time to time in the Company’s publicly disseminated documents and filings. The Company has based the forward-looking statements included in this press release on information available to it on the date of this press release, and the Company assumes no obligation to update any such forward-looking statements. The Company undertakes no obligation to revise or update any forward-looking statements, whether as a result of new information, future events or otherwise, you are advised to consult any additional disclosures that it may make directly to you or through reports that the Company in the future may file with the Securities and Exchange Commission, including annual reports on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K.

Contacts

Investor Relations:
Oaktree Specialty Lending Corporation
Dane Kleven
(213) 356-3260
[email protected]



indie Semiconductor Reports Fourth Quarter 2024 Earnings

indie Semiconductor Reports Fourth Quarter 2024 Earnings

  • Delivers Q4 2024 Revenue of $58.0M, up 7.5% sequentially, with Non-GAAP Gross Margin of 50.4%
  • Prospects for indie remain positive throughout 2025, underpinned by strong design win momentum and key program status despite challenging automotive market environment

ALISO VIEJO, Calif.–(BUSINESS WIRE)–
indie Semiconductor, Inc. (Nasdaq: INDI), an automotive solutions innovator, today announced fourth quarter results for the period ended December 31, 2024. Fourth quarter 2024 revenue increased 7.5%sequentially to $58.0 million, at the mid-point of the outlook with Non-GAAP gross margin sequentially flat at 50.4 percent. On a GAAP basis, fourth quarter 2024 operating loss was $33.9 million compared to $21.6 million a year ago. Non-GAAP operating loss for the fourth quarter of 2024 was $14.2 million, versus $2.4 million during the same period last year. Fourth quarter 2024 GAAP loss per share was $0.18, while Non-GAAP loss per share was $0.07.

“In Q4, indie delivered growth despite a challenging market backdrop,” said Donald McClymont, indie’s co-founder and chief executive officer. “This resilient business performance is a testament to our class-leading, highly differentiated product portfolio, our relentless focus on our key target markets and our unique customer relationships. This technology leadership position will also ensure that we drive growth throughout 2025 and beyond,” added McClymont.

Business Highlights

  • Flagship ADAS programs on track for second half 2025 initial volume shipments
  • Secured design win for Vision processor with large Korean OEM for front sensing and interior monitoring
  • Captured new design-wins for Vision processor with multiple Chinese OEMs for multi-channel applications such as eMirror
  • Validated performance of initial samples of 120 GHz radar solution for in-cabin occupant monitoring
  • Achieved ASIL-D certification (the highest level of functional safety) for electrification ASIC
  • Commenced turnkey optical component integration capability for automotive and mobility applications

Q1 2025 Outlook

We provide guidance on a non-GAAP basis only because certain information necessary to reconcile such results and guidance to GAAP is difficult to estimate and dependent on future events outside of our control and, therefore, is not available without unreasonable efforts. Please refer to the header captioned “Discussion Regarding the Use of Non-GAAP Financial Measures” in this release for a further discussion of our use of non-GAAP measures.

With the backdrop of increased market uncertainty, causing slower than anticipated production ramps for the first quarter of 2025, indie expects revenue between $52.5 and $57.5 million or $55 million at the mid-point, down 5.2% sequentially and an increase of 5.1% year over year, with Non-GAAP gross margin between 49% and 50%. Given indie’s multiple new products ramping throughout 2025,the outlook remains positive.

indie’s Q4 2024 Conference Call

indie Semiconductor will host a conference call with analysts to discuss its fourth quarter 2024 results and business outlook today February 20,2025 at 5:00 p.m. Eastern time. To listen to the conference call via the Internet, please go to the Financials tab on the Investors page of indie’s website to listen to the conference call via telephone, please call (877) 451-6152 (domestic) or (201) 389-0879 (international), Conference ID: 13750526.

A replay of the conference call will be available beginning at 9:00 p.m. Eastern time on February 20, 2025, until 11:59 p.m. Eastern time on March 6, 2025, under the Financials tab on the Investors page of indie’s website, or by calling (844) 512-2921 (domestic) or (412) 317-6671 (international), Access ID: 13750526.

About indie

Headquartered in Aliso Viejo, CA, indie is empowering the automotive revolution with next generation semiconductors, photonics and software platforms. We focus on developing innovative, high-performance and energy-efficient technology for ADAS, in-cabin user experience and electrification applications. Our mixed-signal SoCs enable edge sensors spanning Radar, LiDAR, Ultrasound, and Computer Vision, while our embedded system control, power management and interfacing solutions transform the in-cabin experience and accelerate increasingly automated and electrified vehicles. As a global innovator, we are an approved vendor to Tier 1 partners and our solutions can be found in marquee automotive OEMs worldwide.

Please visit us at www.indie.inc to learn more.

Safe Harbor Statement

This communication contains “forward-looking statements” (including within the meaning of Section 21E of the United States Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended). Such statements can be identified by words such as “will likely result,” “expect,” “anticipate,” “estimate,” “believe,” “intend,” “plan,” “project,” “outlook,” “should,” “could,” “may” or words of similar meaning and include, but are not limited to, statements regarding our future business and financial performance and prospects, including statements regarding general and automotive market conditions, expectations regarding our multiple product ramps in 2025 and our belief that we will drive growth throughout 2025 and beyond. Such forward-looking statements are based upon the current beliefs and expectations of our management and are inherently subject to significant business, economic and competitive uncertainties and contingencies, many of which are difficult to predict and generally beyond our control. Actual results and the timing of events may differ materially from the results included in such forward-looking statements. In addition to the factors previously disclosed in our Annual Report on Form 10-K for the fiscal year ended December 31, 2023 filed with the SEC on February 29, 2024 (and as amended by Amendment No. 1 to the Form 10-K filed with the SEC on March 20, 2024) and in our other public reports filed with the SEC (including those identified under “Risk Factors” therein), the following factors, among others, could cause actual results and the timing of events to differ materially from the anticipated results or other expectations expressed in the forward-looking statements: macroeconomic conditions, including inflation, rising interest rates and volatility in the credit and financial markets, our reliance on contract manufacturing and outsourced supply chain and the availability of semiconductors and manufacturing capacity; competitive products and pricing pressures; our ability to win competitive bid selection processes and achieve additional design wins; the impact of recent acquisitions made and any other acquisitions we may make, including our ability to successfully integrate acquired businesses and risks that the anticipated benefits of any acquisitions may not be fully realized or take longer to realize than expected; our ability to develop, market and gain acceptance for new and enhanced products and expand into new technologies and markets; current and potential trade restrictions and trade tensions, including the recent trade and tariff actions taken or proposed by the US government affecting the countries where we operate and political or economic instability in our target markets. All forward-looking statements in this press release are expressly qualified in their entirety by the foregoing cautionary statements.

Investors are cautioned not to place undue reliance on the forward-looking statements in this press release, which information set forth herein speaks only as of the date hereof. We do not undertake, and we expressly disclaim, any intention or obligation to update any forward-looking statements made in this announcement or in our other public filings, whether as a result of new information, future events or otherwise, except as required by law.

#indieSemi_Earnings

INDIE SEMICONDUCTOR, INC.

PRELIMINARY CONSOLIDATED STATEMENTS OF OPERATIONS

(Amounts in thousands, except share and per share amounts)

(Unaudited)

 

 

Three Months Ended

December 31,

 

Year Ended

December 31,

 

 

2024

 

 

 

2023

 

 

 

2024

 

 

 

2023

 

 

 

 

 

 

 

 

 

Revenue:

 

 

 

 

 

 

 

Product revenue

 

53,826

 

 

 

63,153

 

 

 

202,698

 

 

 

195,624

 

Contract revenue

 

4,183

 

 

 

6,980

 

 

 

13,984

 

 

 

27,545

 

Total revenue

 

58,009

 

 

 

70,133

 

 

 

216,682

 

 

 

223,169

 

Operating expenses:

 

 

 

 

 

 

 

Cost of goods sold

 

33,313

 

 

 

42,236

 

 

 

126,373

 

 

 

133,606

 

Research and development

 

38,254

 

 

 

34,281

 

 

 

175,112

 

 

 

154,507

 

Selling, general, and administrative

 

20,328

 

 

 

15,187

 

 

 

80,945

 

 

 

70,479

 

Restructuring costs

 

10

 

 

 

 

 

 

4,332

 

 

 

 

Total operating expenses

 

91,905

 

 

 

91,704

 

 

 

386,762

 

 

 

358,592

 

Loss from operations

 

(33,896

)

 

 

(21,571

)

 

 

(170,080

)

 

 

(135,423

)

Other income (expense), net:

 

 

 

 

 

 

 

Interest income

 

1,209

 

 

 

1,654

 

 

 

4,588

 

 

 

7,801

 

Interest expense

 

(2,838

)

 

 

(2,116

)

 

 

(9,258

)

 

 

(8,650

)

Gain from change in fair value of warrants

 

 

 

 

13,692

 

 

 

 

 

 

7,066

 

Gain (loss) from change in fair value of contingent considerations and acquisition-related holdbacks

 

874

 

 

 

(7,193

)

 

 

29,041

 

 

 

(2,985

)

Other expense

 

(302

)

 

 

(912

)

 

 

(400

)

 

 

(1,175

)

Total other income (loss), net

 

(1,057

)

 

 

5,125

 

 

 

23,971

 

 

 

2,057

 

Net loss before income taxes

 

(34,953

)

 

 

(16,446

)

 

 

(146,109

)

 

 

(133,366

)

Income tax benefit (provision)

 

(340

)

 

 

1,820

 

 

 

998

 

 

 

4,534

 

Net loss

 

(35,293

)

 

 

(14,626

)

 

 

(145,111

)

 

 

(128,832

)

Less: Net income (loss) attributable to noncontrolling interest

 

(1,867

)

 

 

29

 

 

 

(11,664

)

 

 

(11,207

)

Net loss attributable to indie Semiconductor, Inc.

 

(33,426

)

 

 

(14,655

)

 

 

(133,447

)

 

 

(117,625

)

 

 

 

 

 

 

 

 

Net loss attributable to common shares — basic

 

(33,426

)

 

 

(14,655

)

 

 

(133,447

)

 

 

(117,625

)

Net loss attributable to common shares — diluted

 

(33,426

)

 

 

(14,655

)

 

 

(133,447

)

 

 

(117,625

)

 

 

 

 

 

 

 

 

Net loss per share attributable to common shares — basic

$

(0.18

)

 

$

(0.09

)

 

$

(0.76

)

 

$

(0.81

)

Net loss per share attributable to common shares — diluted

$

(0.18

)

 

$

(0.09

)

 

$

(0.76

)

 

$

(0.81

)

 

 

 

 

 

 

 

 

Weighted average common shares outstanding — basic

 

185,682,996

 

 

 

159,996,055

 

 

 

175,029,650

 

 

 

145,188,867

 

Weighted average common shares outstanding — diluted

 

185,682,996

 

 

 

159,996,055

 

 

 

175,029,650

 

 

 

145,188,867

 

INDIE SEMICONDUCTOR, INC.

PRELIMINARY CONSOLIDATED BALANCE SHEETS

(Amounts in thousands)

(Unaudited)

 

 

December 31, 2024

 

December 31,

2023

Assets

 

 

 

Current assets:

 

 

 

Cash and cash equivalents

$

274,248

 

 

$

151,678

 

Restricted cash

 

10,300

 

 

 

 

Accounts receivable, net

 

52,005

 

 

 

63,602

 

Inventory, net

 

49,887

 

 

 

33,141

 

Prepaid expenses and other current assets

 

22,308

 

 

 

23,399

 

Total current assets

 

408,748

 

 

 

271,820

 

Property and equipment, net

 

34,281

 

 

 

26,966

 

Intangible assets, net

 

208,944

 

 

 

208,134

 

Goodwill

 

266,368

 

 

 

295,096

 

Operating lease right-of-use assets

 

16,107

 

 

 

13,790

 

Other assets and deposits

 

6,938

 

 

 

3,070

 

Total assets

$

941,386

 

 

$

818,876

 

 

 

 

 

Liabilities and stockholders’ equity

 

 

 

Accounts payable

$

28,326

 

 

$

18,405

 

Accrued payroll liabilities

 

5,573

 

 

 

6,621

 

Contingent considerations

 

3,589

 

 

 

83,903

 

Accrued expenses and other current liabilities

 

30,188

 

 

 

21,411

 

Intangible asset contract liability

 

5,875

 

 

 

4,429

 

Current debt obligations

 

12,220

 

 

 

4,106

 

Total current liabilities

 

85,771

 

 

 

138,875

 

Long-term debt, net of current portion

 

369,097

 

 

 

156,735

 

Intangible asset contract liability, net of current portion

 

11,965

 

 

 

 

Deferred tax liabilities, non-current

 

11,660

 

 

 

13,696

 

Operating lease liability, non-current

 

14,278

 

 

 

10,850

 

Other long-term liabilities

 

4,111

 

 

 

21,695

 

Total liabilities

$

496,882

 

 

$

341,851

 

Commitments and contingencies

 

 

 

Stockholders’ equity

 

 

 

Preferred stock

$

 

 

$

 

Class A common stock

 

19

 

 

 

16

 

Class V common stock

 

2

 

 

 

2

 

Additional paid-in capital

 

936,563

 

 

 

813,742

 

Accumulated deficit

 

(494,888

)

 

 

(361,441

)

Accumulated other comprehensive loss

 

(24,622

)

 

 

(6,170

)

indie’s stockholders’ equity

 

417,074

 

 

 

446,149

 

Noncontrolling interest

 

27,430

 

 

 

30,876

 

Total stockholders’ equity

 

444,504

 

 

 

477,025

 

Total liabilities and stockholders’ equity

$

941,386

 

 

$

818,876

 

INDIE SEMICONDUCTOR, INC.

RECONCILIATION OF PRELIMINARY NON-GAAP MEASURES TO GAAP

(Unaudited)

GAAP refers to financial information presented in accordance with U.S. Generally Accepted Accounting Principles. This press release includes non-GAAP financial measures, as defined in Regulation G promulgated by the Securities and Exchange Commission. We believe that our presentation of non-GAAP financial measures provides useful supplementary information to investors. The presentation of non-GAAP financial measures is not meant to be considered in isolation from or as a substitute for results prepared in accordance with GAAP.

The reconciliations of our preliminary GAAP to non-GAAP measures are as follows (in thousands, except share and per share amounts):

 

Three Months Ended

December 31,

 

Year Ended

December 31,

 

 

2024

 

 

 

2023

 

 

 

2024

 

 

 

2023

 

Computation of non-GAAP gross margin:

 

 

 

 

 

 

 

GAAP revenue

$

58,009

 

 

$

70,133

 

 

$

216,682

 

 

$

223,169

 

GAAP cost of goods sold

 

33,313

 

 

 

42,236

 

 

 

126,373

 

 

 

133,606

 

Acquisition-related expenses

 

(646

)

 

 

(5,983

)

 

 

(1,340

)

 

 

(11,967

)

Amortization of intangible assets

 

(3,732

)

 

 

(1,580

)

 

 

(16,323

)

 

 

(12,509

)

Inventory cost realignments

 

 

 

 

(1,413

)

 

 

(145

)

 

 

(2,778

)

Share-based compensation

 

(164

)

 

 

(111

)

 

 

(1,012

)

 

 

(360

)

Non-GAAP gross profit

$

29,238

 

 

$

36,984

 

 

$

109,129

 

 

$

117,177

 

Non-GAAP gross margin

 

50.4

%

 

 

52.7

%

 

 

50.4

%

 

 

52.5

%

 

Three Months Ended

December 31,

 

Year Ended

December 31,

 

 

2024

 

 

 

2023

 

 

 

2024

 

 

 

2023

 

Computation of non-GAAP operating loss:

 

 

 

 

 

 

 

GAAP loss from operations

$

(33,896

)

 

$

(21,571

)

 

$

(170,080

)

 

$

(135,423

)

Acquisition-related and other non-recurring professional expenses

 

1,648

 

 

 

8,538

 

 

 

5,596

 

 

 

19,417

 

Amortization of intangible assets

 

5,786

 

 

 

2,834

 

 

 

25,645

 

 

 

20,566

 

Inventory cost realignments

 

 

 

 

1,413

 

 

 

145

 

 

 

2,778

 

Share-based compensation

 

12,258

 

 

 

6,371

 

 

 

68,997

 

 

 

44,082

 

Restructuring costs

 

10

 

 

 

 

 

 

4,332

 

 

 

 

Non-GAAP operating loss

$

(14,194

)

 

$

(2,415

)

 

$

(65,365

)

 

$

(48,580

)

 

Three Months Ended

December 31,

 

Year Ended

December 31,

 

 

2024

 

 

 

2023

 

 

 

2024

 

 

 

2023

 

Computation of non-GAAP net loss:

 

 

 

 

 

 

 

Net loss

$

(35,293

)

 

$

(14,626

)

 

$

(145,111

)

 

$

(128,832

)

Acquisition-related and other non-recurring professional expenses

 

1,648

 

 

 

8,538

 

 

 

5,596

 

 

 

19,417

 

Amortization of intangible assets

 

5,786

 

 

 

2,834

 

 

 

25,645

 

 

 

20,566

 

Inventory cost realignments

 

 

 

 

1,413

 

 

 

145

 

 

 

2,778

 

Share-based compensation

 

12,258

 

 

 

6,371

 

 

 

68,997

 

 

 

44,082

 

Restructuring costs

 

10

 

 

 

 

 

 

4,332

 

 

 

 

Gain from change in fair value of warrants

 

 

 

 

(13,692

)

 

 

 

 

 

(7,066

)

(Gain) loss from change in fair value of contingent considerations and acquisition-related holdbacks

 

(874

)

 

 

7,193

 

 

 

(29,041

)

 

 

2,985

 

Other expense

 

302

 

 

 

912

 

 

 

400

 

 

 

1,175

 

Non-cash interest expense

 

409

 

 

 

274

 

 

 

1,172

 

 

 

995

 

Income tax benefit (provision)

 

340

 

 

 

(1,820

)

 

 

(998

)

 

 

(4,534

)

Non-GAAP net loss

$

(15,414

)

 

$

(2,603

)

 

$

(68,863

)

 

$

(48,434

)

 

Three Months Ended

December 31,

 

Year Ended

December 31,

 

 

2024

 

 

 

2023

 

 

 

2024

 

 

 

2023

 

Computation of Non-GAAP EBITDA:

 

 

 

 

 

 

 

Net loss

$

(35,293

)

 

$

(14,626

)

 

$

(145,111

)

 

$

(128,832

)

Interest income

 

(1,209

)

 

 

(1,654

)

 

 

(4,588

)

 

 

(7,801

)

Interest expense

 

2,838

 

 

 

2,116

 

 

 

9,258

 

 

 

8,650

 

Gain from change in fair value of warrants

 

 

 

 

(13,692

)

 

 

 

 

 

(7,066

)

(Gain) loss from change in fair value of contingent considerations and acquisition-related holdbacks

 

(874

)

 

 

7,193

 

 

 

(29,041

)

 

 

2,985

 

Other expenses

 

302

 

 

 

912

 

 

 

400

 

 

 

1,175

 

Income tax benefit (provision)

 

340

 

 

 

(1,820

)

 

 

(998

)

 

 

(4,534

)

Depreciation and amortization

 

7,673

 

 

 

4,286

 

 

 

32,489

 

 

 

25,134

 

Stock-based compensation

 

12,258

 

 

 

6,371

 

 

 

68,997

 

 

 

44,082

 

Inventory cost realignments

 

 

 

 

1,413

 

 

 

145

 

 

 

2,778

 

Acquisition-related and other non-recurring professional expenses

 

1,648

 

 

 

8,538

 

 

 

5,596

 

 

 

19,417

 

Restructuring costs

 

10

 

 

 

 

 

 

4,332

 

 

 

 

Non-GAAP EBITDA

$

(12,307

)

 

$

(963

)

 

$

(58,521

)

 

$

(44,012

)

 

Three Months Ended

December 31, 2024

Computation of non-GAAP share count:

 

Weighted Average Class A common stock – Basic

 

185,682,996

 

Weighted Average Class V common stock – Basic

 

17,671,247

 

Escrow Shares

 

1,725,000

 

TeraXion Unexercised Options

 

627,663

 

Non-GAAP share count

 

205,706,906

 

 

 

Non-GAAP net loss

$

(15,414

)

Non-GAAP net loss per share

$

(0.07

)

Discussion Regarding the Use of Non-GAAP Financial Measures

Our earnings release contains some or all of the following financial measures that have not been calculated in accordance with United States Generally Accepted Accounting Principles (“GAAP”): (i) non-GAAP gross profit and gross margin, (ii) non-GAAP operating loss, (iii) non-GAAP net loss, (iv) non-GAAP EBITDA, (v) non-GAAP share count, (vi) non-GAAP net loss and (vii) non-GAAP net loss per share. As set forth in the tables above, we derive such non-GAAP financial measures by excluding certain expenses and other items from the respective GAAP financial measure that is most directly comparable to each non-GAAP financial measure. Management may use these non-GAAP financial measures to, amongst other things, evaluate operating performance and compare it against past periods or against peer companies, make operating decisions, forecast for future periods and to determine payments under compensation programs. These non-GAAP financial measures provide management with additional means to understand and evaluate the operating results and trends in our ongoing business by eliminating certain expenses and other items that management believes might otherwise make comparisons of our ongoing business with prior periods and competitors more difficult, obscure trends in ongoing operations or improve management’s ability to forecast future periods.

We provide investors with non-GAAP gross profit and gross margin, non-GAAP operating loss, non-GAAP net loss and non-GAAP net loss per share because we believe it is important for investors to be able to closely monitor and understand changes in our ability to generate income from ongoing business operations. We believe these non-GAAP financial measures give investors an additional method to evaluate historical operating performance and identify trends, an additional means of evaluating period-over-period operating performance and a method to facilitate certain comparisons of our operating results to those of our peer companies. We further believe these non-GAAP financial measures allow investors to assess the overall financial performance of our ongoing operations by eliminating the impact of (i) acquisition-related and other non-recurring professional expenses (including acquisition-related or other non-recurring professional fees and legal expenses, deemed compensation expense and expenses recognized in relation to changes in contingent consideration obligations), (ii) amortization of acquisition-related intangibles and certain license rights, (iii) inventory cost realignments, (iv) gains or losses recognized in relation to changes in the fair value of warrants, contingent considerations issued by indie, acquisition-related holdbacks and unrealized gains or losses from currency hedging contracts, (v) non-cash interest expenses related to the amortization of debt discounts and issuance costs, (vi) share-based compensation, and (vii) income tax benefit (expenses). We believe that disclosing these non-GAAP financial measures contributes to enhanced financial reporting transparency and provides investors with added clarity about complex financial performance measures.

We do not report a GAAP measure of gross profit or gross margin because certain costs related to contract revenues are expensed as incurred and included in research and development expenses, and not in cost of sales, as it is not practicable for us to bifurcate these expenses. We derive and reconcile non-GAAP gross profit from the most relevant GAAP financial measures by subtracting GAAP cost of sales, adjusted for acquisition-related and other non-recurring professional expenses and share-based compensation, from GAAP revenue. We calculate non-GAAP operating loss by excluding from GAAP operating loss, any (i) acquisition-related and other non-recurring professional expenses (including acquisition-related or other non-recurring professional fees and legal expenses, deemed compensation expense and expenses recognized in relation to changes in contingent consideration obligations), (ii) amortization of acquisition-related intangibles and certain license rights, (iii) inventory cost realignments and (iv) share-based compensation. We calculate non-GAAP net loss by excluding from GAAP net income (loss), any (i) acquisition-related and other non-recurring professional expenses (including acquisition-related or non-recurring professional fees and legal expenses, deemed compensation expense and expenses recognized in relation to changes in contingent consideration obligations), (ii) amortization of acquisition-related intangibles and certain license rights, (iii) inventory cost realignments, (iv) gains or losses recognized in relation to changes in the fair value of warrants, contingent considerations issued by indie, acquisition-related holdbacks and unrealized gains or losses from currency hedging contracts, (v) non-cash interest expenses related to the amortization of debt discounts and issuance costs, (vi) share-based compensation, and (vii) income tax benefit (expenses). We calculate non-GAAP EBITDA by excluding from GAAP net income (loss), any (i) acquisition-related and other non-recurring professional expenses (including acquisition-related or non-recurring professional fees and legal expenses, deemed compensation expense and expenses recognized in relation to changes in contingent consideration obligations), (ii) amortization of acquisition-related intangibles and certain license rights, (iii) depreciation of fixed assets, (iv)inventory cost realignments, (v) gains or losses recognized in relation to changes in the fair value of warrants, contingent considerations issued by indie, acquisition-related holdbacks and unrealized gains or losses from currency hedging contracts, (vi) non-cash interest expenses related to the amortization of debt discounts and issuance costs, (vii) share-based compensation, and (viii) income tax benefit (expenses). We calculate non-GAAP share count by adding (i) weighted average Class A common stock, (ii) weighted average Class V common stock held by minority shareholders, which are exchangeable into Class A common stock, (iii) Escrow Shares and (iv) vested but unexercised options issued as part of the TeraXion acquisition. Non-GAAP net loss per share is calculated by dividing non-GAAP net loss by non-GAAP share count.

We exclude the items identified above from the respective non-GAAP financial measure referenced above for the reasons set forth with respect to each such excluded item below:

Acquisition-related and other non-recurring professional expenses – including such items as, when applicable, fair value charges incurred upon the sale of acquired inventory, accounting impact to the cost of goods sold due to one-time inventory costing realignment with a specific supplier, acquisition-related professional fees and legal expenses and other professional fees that are non-recurring in nature because they are not considered by management in making operating decisions and we believe that such expenses do not have a direct correlation to our future business operations and thereby including such charges do not necessarily reflect the performance of our ongoing operations for the period in which such charges or reversals are incurred.

Amortization expenses – related to the amortization expense for acquired intangible assets and certain license rights.

Depreciation expenses – related to the depreciation expenses for all property and equipment on hand.

Inventory cost realignments – related to the supplier allocation premiums introduced during COVID that is currently incorporated in our inventory cost but have since been eliminated going forward. The impact of this premium is deemed non-recurring and therefore not considered by management in its evaluation of the ongoing performance of the business.

Share-based compensation – related to the non-cash compensation expense associated with equity awards granted to our employees (including those granted in lieu of cash compensation) and employer tax related to employee stock transactions. These expenses are not considered by management in making operating decisions and such expenses do not have a direct correlation to our future business operations.

Restructuring costs – related to the one-time expenses the Company incurs to reorganize its operations, which is primarily related to workforce reduction, facilities and other purchase commitment charges.

Gain (loss) from change in fair values – because these adjustments (1) are not considered by management in making operating decisions, (2) are not directly controlled by management, (3) do not necessarily reflect the performance of our ongoing operations for the period in which such charges are recognized and (4) cannot make comparisons between peer company performance less reliable.

Non-cash interest expense – related to the amortization of debt discounts and issuance costs because (1) these expenses are not considered by management in making decision with respect to financing decisions, and (2) these generally reflect non-cash costs.

Income tax benefit (expense) – related to the estimated income tax benefit (expense) that does not result in a current period tax refunds (payments).

The non-GAAP financial measures presented should not be considered in isolation and are not an alternative for the respective GAAP financial measure that is most directly comparable to each such non-GAAP financial measure. Investors are cautioned against placing undue reliance on these non-GAAP financial measures and are urged to review and consider carefully the adjustments made by management to the most directly comparable GAAP financial measures to arrive at these non-GAAP financial measures. Non-GAAP financial measures may have limited value as analytical tools because they may exclude certain expenses that some investors consider important in evaluating our operating performance or ongoing business performance. Further, non-GAAP financial measures are likely to have limited value for purposes of drawing comparisons between companies as a result of different companies potentially calculating similarly titled non-GAAP financial measures in different ways because non-GAAP measures are not based on any comprehensive set of accounting rules or principles.

Non-GAAP EBITDA is calculated by removing non-recurring, irregular and one-time items that may distort EBITDA, to the current non-GAAP financial measures. We calculate non-GAAP EBITDA by excluding from GAAP net income (loss), any (i) acquisition-related and other non-recurring expenses (including acquisition-related or other non-recurring professional fees and legal expenses, deemed compensation expense and expenses recognized in relation to changes in contingent consideration obligations), (ii) amortization of acquisition-related intangibles and certain license rights, (iii) depreciation of property, plant and equipment, (iv) inventory cost realignments, (v) gains or losses recognized in relation to changes in the fair value of warrants, contingent considerations issued by indie, acquisition-related holdbacks and unrealized gains or losses from currency hedging contracts, (vi) non-cash interest expenses related to the amortization of debt discounts and issuance costs, (vii) share-based compensation, and (viii) income tax benefit (expenses).

To the extent our disclosures contain forward-looking estimates of non-GAAP financial measures, such as our forward-looking outlook for non-GAAP EBITDA, these measures are provided to investors on a prospective basis for the same reasons (set forth above) we provide them to investors on a historical basis. We are generally unable to provide a reconciliation of our forward-looking non-GAAP measures because certain information needed to make a reasonable forward-looking estimate of such non-GAAP measures are difficult to predict and estimate and is often dependent on future events that may be uncertain or outside of our control and, therefore, is not available without unreasonable efforts. Such events may include unanticipated changes in our GAAP effective tax rate, unanticipated one-time charges related to asset impairments (fixed assets, inventory, intangibles, or goodwill), unanticipated acquisition-related and other non-recurring professional expenses, unanticipated settlements, gains, losses and impairments and other unanticipated items not reflective of ongoing operations. Our forward-looking estimates of both GAAP and non-GAAP measures of our financial performance may differ materially from our actual results and should not be relied upon as statements of fact.

Media Inquiries

[email protected]

Investor Relations

[email protected]

KEYWORDS: United States North America California

INDUSTRY KEYWORDS: Start-Up Semiconductor Professional Services Technology Software

MEDIA:

Logo
Logo